β-Arrestins: Multifunctional signaling adaptors in type 2 diabetes

Molecular Biology Reports

Volumn 38, Issue 4, 2011, Pages 2517-2528

  Feng, Xiaotao ^a   Wang, Wenjian ^a,b   Liu, Jibo ^a   Liu, Yi ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Arrestin; Insulin resistance; Lipotoxicity; Signal transduction; Type 2 diabetes

Indexed keywords

BETA ARRESTIN 1; BETA ARRESTIN 2; FATTY ACID; G PROTEIN COUPLED RECEPTOR; GLUCAGON LIKE PEPTIDE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PIOGLITAZONE; PROTEIN MDM2; ROSIGLITAZONE; BETA ARRESTIN; RETINA S ANTIGEN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; DIABETOGENESIS; HORMONAL REGULATION; HORMONE ACTION; HUMAN; HYPERINSULINEMIA; INSULIN RELEASE; INSULIN RESISTANCE; LIPOTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; BIOLOGICAL MODEL; GENETICS; METABOLISM;

ARRESTINS; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; MODELS, BIOLOGICAL; PHOSPHATIDYLINOSITOL 3-KINASES; SIGNAL TRANSDUCTION;

EID: 79960940602     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-010-0389-3     Document Type: Review

References (115)

1. Kuhn H (1978) Light-regulated binding of rhodopsin kinase and other proteins to cattle photoreceptor membranes. Biochemistry 17:4389-4395
2. Kuhn H, Hall SW, Wilden U (1984) Light-induced binding of 48-kDa protein to photoreceptor membranes is highly enhanced by phosphorylation of rhodopsin. FEBS Lett 176:473-478. doi: 10.1016/0014-5793(84)81221-1
3. Kingsmore SF, Peppel K, Suh D, Caron MG, Lefkowitz RJ, Seldin MF (1995) Genetic mapping of the beta-arrestin 1 and 2 genes on mouse chromosomes 7 and 11 respectively. Mamm Genome 6:306-307
4. Gurevich VV, Gurevich EV (2006) The structural basis of arrestin-mediated regulation of G protein coupled receptor. Pharmacol Ther 110:465-502. doi:10.1016/j.pharmthera.2005.09.008
5. Claing A, Laporte SA, Caron MG, Lefkowitz RJ (2002) Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog Neurobiol 66:61-79. doi:10.1016/S0301-0082(01) 00023-5
6. Hupfeld CJ, Olefsky JM (2007) Regulation of receptor tyrosine kinase signaling by GRKs and beta-arrestins. Annu Rev Physiol 69:561-577. doi:10.1146/annurev.physiol.69.022405.154626
7. Noma T, Lemaire A, Naga Prasad SV, Barki-Harrington L, Tilley DG, Chen J, Le Corvoisier P, Violin JD, Wei H, Lefkowitz RJ, Rockman HA (2007) beta-Arrestin-mediated beta(1)-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 117:2445-2458. doi:10.1172/JCI31901
8. Kovacs JJ, Hara MR, Davenport CL, Kim J, Lefkowitz RJ (2009) Arrestin development: emerging roles for b-arrestins in developmental signaling pathways. Dev Cell 17:443-458. doi: 10.1016/j.devcel.2009.09.011
9. Gao H, Sun Y, Wu Y, Luan B, Wang Y, Qu B, Pei G (2004) Identification of beta-arrestin2 as a G protein-coupled receptorstimulated regulator of NF-kappaB pathways. Mol Cell 14:303-317. doi:10.1016/S1097-2765(04)00216-3
10. Shoelson SE, Lee J, Yuan M (2003) Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity-and diet-induced insulin resistance. Int J Obes Relat Metab Disord 27:S49-S52. doi:10.1038/sj.ijo.0802501
11. Burgering BM, Coffer PJ (1995) Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376:599-602. doi:10.1038/376599a0
12. Taniguchi CM, Emanuelli B, Kahn CR (2006) Critical nodes in signalling pathways: insights into insulin action. Nat Rev Cell Biol 7:86-96. doi:10.1038/nrm1837
13. de Luca C, Olefsky JM (2008) Inflammation and insulin resistance. FEBS Lett 582:97-105. doi:10.1016/j.febslet.2007.11.057
14. Barma P, Bhattacharya S, Bhattacharya A, Kundu R, Dasgupta S, Biswas A, Bhattacharya S, Roy SS, Bhattacharya S (2009) Lipid induced overexpression of NF-jB in skeletal muscle cells is linked to insulin resistance. Biochim Biophys Acta 1792:190-200. doi:10.1016/j.bbadis.2008.11.014
15. Gurevich EV, Gurevich VV (2006) Arrestins: ubiquitous regulators of cellular signaling pathways. Genome Biol 7:236. doi: 10.1186/gb-2006-7-9-236
16. Granzin J, Wilden U, Choe HW, Labahn J, Krafft B, Büldt G (1998) X-ray crystal structure of arrestin from bovine rod outer segments. Nature 391:918-921. doi:10.1038/36147
17. Han M, Gurevich VV, Vishnivetskiy SA, Sigler PB, Schubert C (2001) Crystal structure of beta-arrestin at 1.9 A: possible mechanism of receptor binding and membrane. Structure 9:869-880. doi:10.1015/s0969-2126(01)00644-x
18. Sutton RB, Vishnivetskiy SA, Robert J, Hanson SM, Raman D, Knox BE, Kono M, Navarro J, Gurevich VV (2005) Crystal structure of cone arrestin at 2.3 A: evolution of receptor specificity. J Mol Biol 354:1069-1080. doi:10.1016/j.jmb.2005. 10.023
19. Milano SK, Kim YM, Stefano FP, Benovic JL, Brenner C (2006) Nonvisual arrestin oligomerization and cellular localization are regulated by inositol hexakisphosphate binding. J Biol Chem 281:9812-9823. doi:10.1074/jbc.M512703200
20. Milano SK, Pace HC, Kim YM, Brenner C, Benovic JL (2002) Scaffolding functions of arrestin-2 revealed by crystal structure and mutagenesis. Biochemistry 41:3321-3328. doi:10.1021/ bi015905j
21. Nobles KN, Guan Z, Xiao K, Oas TG, Lefkowitz RJ (2007) The active conformation of beta-arrestin1: direct evidence for the phosphate sensor in the N-domain and conformational differences in the active states of beta-arrestins-1 and-2. J Biol Chem 282:21370-21381. doi:10.1074/jbc.M611483200
22. Xiao K, Shenoy SK, Nobles K, Lefkowitz RJ (2004) Activationdependent conformational changes in beta-arrestin 2. J Biol Chem 279:55744-55753. doi:10.1074/jbc.M409785200
23. Hanson SM, Van Eps N, Francis DJ, Altenbach C, Vishnivetskiy SA, Arshavsky VY, Klug CS, Hubbell WL, Gurevich VV (2007) Structure and function of the visual arrestin oligomer. EMBO J 26:1726-1736. doi:10.1038/sj.emboj.7601614
24. Imamoto Y, Tamura C, Kamikubo H, Kataoka M (2003) Concentration-dependent tetramerization of bovine visual arrestin. Biophys J 85:1186-1195. doi:10.1016/S0006-3495(03)74554-8
25. Povsic TJ, Kohout TA, Lefkowitz RJ (2003) beta-Arrestin1 mediates insulin-like growth factor 1 (IGF-1) activation of phosphatidylinositol 3-kinase (PI3K) and anti-apoptosis. J Biol Chem 278:51334-51339. doi:10.1074/jbc. M309968200
26. Zhande R, Mitchell JJ, Wu J, Sun XJ (2002) Molecular mechanism of insulin-induced degradation of insulin receptor substrate. Mol Cell Biol 22:1016-1026. doi:10.1128/MCB.22.4. 1016-1026.2002
27. Isao UI, Takeshi I, Jie H, Satoh H, Shenoy SK, Lefkowitz RJ, Hupfeld CJ, Olefsky JM (2004) b-Arrestin-1 competitively inhibits insulin-induced ubiquitination and degradation of insulin receptor substrate 1. Mol Cell Biol 24:8929-8937. doi: 10.1128/MCB.24.20.8929-8937.2004
28. Léon S, Haguenauer-Tsapis R (2009) Ubiquitin ligase adaptors: regulators of ubiquitylation and endocytosis of plasma membrane proteins. Exp Cell Res 315:1574-1583. doi:10.1016/ j.yexcr.2008.11.014
29. Kerscher O, Felberbaum R, Hochstrasser M (2006) Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 22:159-180. doi:10.1146/annurev.cellbio.22. 010605.093503
30. Fang S, Weissman AM (2004) A field guide to ubiquitylation. Cell Mol Life Sci 61:1546-1561. doi:10.1007/s00018-004-4129-5
31. Li W, Ye Y (2008) Polyubiquitin: functions, structures, and mechanisms. Cell Mol Life Sci 65:2397-2406. doi:10.1007/ s00018-008-8090-6
32. Li X, Baillie GS, Houslay MD (2009) Mdm2 directs the ubiquitination of beta-arrestin-sequestered cAMP phosphodiesterase-4D5. J Biol Chem 284:16170-16182. doi:10.1074/jbc.M109.00 8078
33. Wang P, Gao H, Ni Y, Wang B, Ji L, Qin L, Ma L, Pei G (2003) beta-Arrestin 2 functions as a G-protein-coupled receptor-activated regulator of oncoprotein Mdm2. J Biol Chem 278: 6363-6370. doi:10.1074/jbc.M210350200
34. Bhandari D, Trejo J, Benovic JL, Marchese A (2007) Arrestin-2 interacts with the ubiquitin-protein isopeptide ligase atrophininteracting protein 4 and mediates endosomal sorting of the chemokine receptor CXCR4. J Biol Chem 282:36971-36979. doi:10.1074/jbc.M705085200
35. Shenoy SK, Lefkowitz RJ (2003) Trafficking patterns of betaarrestin and G protein-coupled receptors determined by the kinetics of beta-arrestin deubiquitination. J Biol Chem 278:14498-14506. doi:10.1074/jbc.M209626200
36. Lefkowitz RJ, Rajagopal K, Whaien EJ (2006) New roles for b-arrestins in cell signaling: not just for seven-transmembrane receptor. Mol Cell 24:643-652. doi:10.1016/j.molcel.2006. 11.007
37. Wang P, Wu Y, Ge X, Ma L, Pei G (2003) Subcellular localization of beta-arrestins is determined by their intact N domain and the nuclear export signal at the C terminus. J Biol Chem 278:11648-11653. doi:10.1074/jbc. M208109200
38. Dalle S, Ricketts W, Imamura T, Vollenweider P, Olefsky JM (2001) Insulin and insulin-like growth factor I receptors utilize different G protein signaling components. J Biol Chem 276:15688-15695. doi:10.1074/jbc.M010884200
39. Luan B, Zhao J, Wu H, Duan B, Shu GW, Wang XY, Li D, Jia W, Kang J, Pei G (2009) Deficiency of a b-arrestin-2 signal complex contributes to insulin resistance. Nature 457:1146-1150. doi:10.1038/nature07617
40. Ahn S, Shenoy SK, Wei H, Lefkowitz RJ (2004) Differential kinetic and spatial patterns of beta-arrestin and G protein-mediated ERK activation by the angiotensin II receptor. J Biol Chem 279:35518-35525. doi:10.1074/jbc.M405878200
41. Guo C, Whitmarsh AJ (2008) The beta-arrestin-2 scaffold protein promotes c-Jun N-terminal kinase-3 activation by binding to its nonconserved N terminus. J Biol Chem 283:15903-15911. doi:10.1074/jbc.M710006200
42. Ahn S, Kim J, Hara MR, Ren XR, Lefkowitz RJ (2009) b-Arrestin-2 mediates anti-apoptotic signaling through regulation of BAD phosphorylation. J Biol Chem 284:8855-8865. doi: 10.1074/jbc.M808463200
43. Wehbi V, Tranchant T, Durand G, Musnier A, Decourtye J, Piketty V, Butnev VY, Bousfield GR, Crépieux P, Maurel MC, Reiter E (2010) Partially deglycosylated equine LH preferentially activates beta-arrestin-dependent signaling at the folliclestimulating hormone receptor. Mol Endocrinol 24:561-573. doi: 10.1210/me.2009-0347
44. Imamura T, Huang J, Dalle S, Ugi S, Usui I, Luttrell LM, Miller WE, Lefkowitz RJ, Olefsky JM (2001) beta-Arrestin-mediated recruitment of the Src family kinase Yes mediates endothelin-1-stimulated glucose transport. J Biol Chem 276:43663-43667. doi:10.1074/jbc.M105364200
45. Jiang T, Qiu Y (2003) Interaction between Src and a C-terminal proline-rich motif of Akt is required for Akt activation. J Biol Chem 278:15789-15793. doi:10.1074/jbc.M212525200
46. Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG (2005) An Akt/b-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122:261-273. doi:10.1016/j.cell.2005.05.012
47. Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V, Wetsel WC, Lefkowitz RJ, Gainetdinov RR, Caron MG (2008) A b-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132:125-136. doi:10.1016/ j.cell.2007.11.041
48. Lodeiro M, Theodorpoulou M, Pardo M, Casanueva FF, Camiña JP (2009) c-Src regulates Akt signaling in response to ghrelin via beta-arrestin signaling-independent and-dependent mechanisms. PLoS ONE 4:e4686. doi:10.1371/journal.pone.0004686
49. Stöckli J, James DE (2009) Insulin action under arrestin. Cell Metab 9:213-214. doi:10.1016/j.cmet.2009.02.005
50. Rodgers JT, Puigserver P (2009) Insulin resistance: b-arrestin development. Cell Res 19:275-276. doi:10.1038/cr.2009.22
51. Lee DF, Kuo HP, Chen CT, Wei Y, Chou CK, Hung JY, Yen CJ, Hung MC (2008) IKKb suppression of TSC1 function links the mTOR pathway with insulin resistance. Int J Mol Med 22:633-638. doi:10.3892/ijmm-00000065
52. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-b and NF-jB. Nat Med 11:183-190. doi:10.1038/nm1166
53. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE (2001) Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikkb. Science 293:1673-1677. doi:10.1126/science. 1061620
54. Moon MK, Kim M, Chung SS, Lee HJ, Koh SH, Svovoda P, Jung MH, Cho YM, Park YJ, Choi SH, Jang HC, Park KS, Lee HK (2010) S-adenosyl-L-methionine ameliorates TNFalphainduced insulin resistance in 3T3-L1 adipocytes. Exp Mol Med 42:345-352. doi:10.3858/emm.2010.42.5.036
55. Lou SY, Liu Y, Chen WH, Ying J, He YM, Wang WJ (2008) Pollen Typhae total flavones inhibit expression of interleukin-6 in C2C12 skeletal muscle cells cultured with palmitate. Zhong Xi Yi Jie He Xue Bao 6:488-492. doi:10.3736/jcim20080511
56. Junqueira AS, Romêo FJ, Junqueira CDL (2009) Evaluation of the degree of vascular inflammation in patients with metabolic syndrome. Arq Bras Cardiol 93:360-366, 353-359. doi: 10.1590/S0066-782X2009001000008
57. Klover PJ, Senn JJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA (2003) Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Biol Chem 178:13740-13746. doi:10.1074/jbc.M210689200
58. Jové M, Planavila A, Laguna JC, Vázquez-Carrera M (2005) Palmitate-induced interleukin 6 production is mediated by protein kinase C and nuclear-factor kappaB activation and leads to glucose transporter 4 down-regulation in skeletal muscle cells. Endocrinology 146:3087-3095. doi:10.1210/en.2004-1560
59. Ko WC, Liu TP, Cheng JT, Tzeng TF, Liu IM (2006) Effect of opioid l-receptors activation on insulin signals damaged by tumor necrosis factor a in myoblast C2C12 cells. Neurosci Lett 397:274-278. doi:10.1016/j.neulet.2005.12. 047
60. Witherow DS, Garrison TR, Miller WE, Lefkowitz RJ (2004) beta-Arrestin inhibits NF-jB activity by means of its interaction with the NF-jB inhibitor IjBa. Proc Natl Acad Sci USA 101:8603-8607. doi:10.1073/pnas.0402851101
61. Mythreye K, Blobe GC (2009) The type III TGF-beta receptor regulates epithelial and cancer cell migration through beta-arrestin2-mediated activation of Cdc42. Proc Natl Acad Sci USA 106:8221-8226. doi:10.1073/pnas.0812879106
62. You HJ, How T, Blobe GC (2009) The type III transforming growth factor-beta receptor negatively regulates nuclear factor kappa B signaling through its interaction with beta-arrestin2. Carcinogenesis 30:1281-1287. doi:10.1093/carcin/bgp071
63. Fan HK, Luttrell LM, Tempel GE, Senn JJ, Halushka PV, Cook JA (2007) b-Arrestins 1 and 2 differentially regulate LPSinduced signaling and pro-inflammatory gene expression. Mol Immunol 44:3092-3099. doi:10.1016/j. molimm.2007.02.009
64. Wang W, Xu M, Zhang YY, He B (2009) Fenoterol, a b2-adrenoceptor agonist, inhibits LPS-induced membrane-bound CD14, TLR4/CD14 complex, and inflammatory cytokines production through b-arrestin-2 in THP-1 cell line. Acta Pharmacol Sin 30:1522-1528. doi:10.1038/aps.2009.153
65. Basher F, Fan H, Zingarelli B, Borg KT, Luttrell LM, Tempel GE, Halushka PV, Cook JA (2008) b-Arrestin 2: a negative regulator of inflammatory responses in polymorphonuclear leukocytes. Int J Clin Exp Med 1:32-41. doi:10.1016/j.cell.2007.11.041
66. Luan B, Zhang ZN, Wu YL, Kang J, Pei G (2005) beta-Arrestin2 functions as a phosphorylation-regulated suppressor of UVinduced NF-kappaB activation. EMBO J 24:4237-4246. doi: 10.1038/sj.emboj.7600882
67. Wang Y, Tang Y, Teng L, Wu Y, Zhao X, Pei G (2006) Association of beta-arrestin and TRAF6 negatively regulates Toll-like receptor-interleukin 1 receptor signaling. Nat Immun 7:139-147. doi:10.1038/ni1294
68. Seregin SS, Appledorn DM, Patial S, Bujold M, Nance W, Godbehere S, Parameswaran N, Amalfitano A (2010) beta-Arrestins modulate adenovirus-vector- induced innate immune responses: differential regulation by beta-arrestin-1 and betaarrestin. Virus Res 147:123-134. doi:10.1016/j.virusres.2009. 10.023
69. Broca C, Quoyer J, Costes S, Linck N, Varrault A, Deffayet PM, Bockaert J, Dalle S, Bertrand G (2009) beta-Arrestin 1 is required for PAC1 receptor-mediated potentiation of long-lasting ERK1/2 activation by glucose in pancreatic beta-cells. J Biol Chem 284:4332-4342. doi:10.1074/jbc.M807595200
70. Sonoda N, Imamura T, Yoshizaki T, Babendure JL, Lu JC, Olefsky JM (2008) b-Arrestin-1 mediates glucagon-like peptide-1 signaling to insulin secretion in cultured pancreatic b cells. Proc Nat Acad Sci USA 105:6614-6619. doi:10.1073/pnas. 0710402105
71. Holz GG (2004) Epac: a new cAMP-binding protein in support of glucagon-likepeptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes 53:5-13. doi:10.2337/ diabetes.53.1.5
72. Burcelin R, Cani PD, Knauf C (2007) Glucagon-like peptide-1 and energy homeostasis. J Nutr 137:2534S-2538S
73. Jorgensen R, Kubale V, Vrecl M, Schwartz TW, Elling CE (2007) Oxyntomodulin differentially affects glucagon-like peptide-1 receptor beta-arrestin recruitment and signaling through Galpha(s). J Pharmacol Exp Ther 322:148-154. doi:10.1124/ jpet.107.120006
74. Doyle ME, Egan JM (2007) Mechanisms of action of glucagonlike peptide 1 in the pancreas. Pharmacol Ther 113:546-593. doi:10.1016/j.pharmthera.2006.11. 007
75. Park S, Dong X, Fisher TL, Dunn S, Omer AK, Weir G, White MF (2006) Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J Biol Chem 281:1159-1168. doi: 10.1074/jbc.M508307200
76. Quoyer J, Longuet C, Broca C, Linck N, Costes S, Varin E, Bockaert J, Bertrand G, Dalle S (2010) GLP-1 mediates antiapototic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cell. J Biol Chem 285:1989-2002. doi:10.1074/jbc.M109.067207
77. Portela-Gomes GM, Lukinius A, Ljungberg O, Efendic S, Ahrén B, Abdel-Halim SM (2003) PACAP is expressed in secretory granules of insulin and glucagon cells in human and rodent pancreas. Evidence for generation of cAMP compartments uncoupled from hormone release in diabetic islets. Regul Pept 113:31-39. doi:10.1016/S0167-0115(02)00295-1
78. Yamamoto K, Hashimoto H, Tomimoto S, Shintani N, Miyazaki J, Tashiro F, Aihara H, Nammo T, Li M, Yamagata Y, Miyagawa JI, Matsuzawa Y, Kawabata Y, Fukuyama Y, Koga K, Mori W, Tanaka K, Matsuda T, Baba A (2003) Overexpression of PACAP in transgenic mouse pancreatic beta-cells enhances insulin secretion and ameliorates streptozotocin-induced diabetes. Diabetes 52:1155-1162. doi:10.2337/diabetes.52.5.1155
79. Dresner A, Laurent D, Marcucci M, Griffin ME, Dufour S, Cline GW, Slezak LA, Andersen DK, Hundal RS, Rothman DL, Petersen KF, Shulman GI (1999) Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 103:253-259. doi:10.1172/JCI5001
80. Kashyap SR, Belfort R, Berria R, Suraamornkul S, Pratipranawatr T, Finlayson J, Barrentine A, Bajaj M, Mandarino L, DeFronzo R, Cusi K (2004) Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. Am J Physiol Endocrinol Metab 287:E537-E546. doi: 10.1152/ajpendo. 00541.2003
81. Haus JM, Solomon TP, Marchetti CM, Edmison JM, González F, Kirwan JP (2010) Free fatty acid-induced hepatic insulin resistance is attenuated following lifestyle intervention in obese individuals with impaired glucose tolerance. J Clin Endocrinol Metab 95:323-327. doi:10.1210/jc.2009-1101
82. Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W, Bajaj M, Mandarino L, DeFronzo R, Cusi K (2003) A sustained increase in plasma free fatty acids impairs insulin secretion in non-diabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 52:2461-2474. doi: 10.2337/diabetes.52.10.2461
83. Chavez JA, Summers SA (2003) Characterizing the effects of saturated fatty acids on insulin signaling and ceramide and diacylglycerol accumulation in 3T3-L1 adipocytes and C2C12 myotubes. Arch Biochem Biophys 419:101-109. doi:10.1016/ j.abb.2003.08.020
84. Nakamura S, Takamura T, Matsuzawa-Nagata N, Takayama H, Misu H, Noda H, Nabemoto S, Kurita S, Ota T, Ando H, Miyamoto K, Kaneko S (2009) Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria. J Biol Chem 284:14809-14818. doi: 10.1074/jbc.M901488200
85. Preitner F, Mody N, Graham TE, Peroni OD, Kahn BB (2009) Long-term Fenretinide treatment prevents high-fat diet-induced obesity, insulin resistance, and hepatic steatosis. Am J Physiol Endorinol Metab 297:E1420-E1429. doi:10.1152/ajpendo.00 362.20090193-1849/09
86. Ehses JA, Meier DT, Wueest S, Rytka J, Boller S, Wielinga PY, Schraenen A, Lemaire K, Debray S, Van Lommel L, Pospisilik JA, Tschopp O, Schultze SM, Malipiero U, Esterbauer H, Ellingsgaard H, Rütti S, Schuit FC, Lutz TA, Böni-Schnetzler M, Konrad D, Donath MY (2010) Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia 53:1795-1806. doi:10.1007/s00125-010- 1747-3
87. Senn JJ (2006) Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes. J Biol Chem 281:26865-26875. doi:10.1074/jbc.M51330 4200
88. Ragheb R, Shanab GM, Medhat AM, Seoudi DM, Adeli K, Fantus IG (2009) Free fatty acid-induced muscle insulin resistance and glucose uptake dysfunction: evidence for PKC activation and oxidative stress-activated signaling pathways. Biochem Biophys Res Commun 389:211-216. doi:10.1016/ j.bbrc.2009.08.106
89. Belfort R, Mandarino L, Kashyap S, Wirfel K, Pratipanawatr T, Berria R, Defronzo RA, Cusi K (2005) Dose response effect of elevated plasma FFA on insulin signaling. Diabetes 54:1640-1648. doi:10.2337/diabetes.54.6.1640
90. Griffin ME, Marcucci MJ, Cline GW, Bell K, Barucci N, Lee D, Goodyear LJ, Kraegen EW, White MF, Shulman GI (1999) Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48:1270-1274. doi:10.2337/diabetes.48.6. 1270
91. Timmers S, Schrauwen P, de Vogel J (2008) Muscular diacylglycerol metabolism and insulin resistance. Physiol Behav 94:242-251. doi:10.1016/j.physbeh.2007.12.002
92. Erion DM, Shulman GI (2010) Diacylglycerol-mediated insulin resistance. Nat Med 16:400-402. doi:10.1038/nm0410-400
93. Morino K, Petersen KF, Dufour S, Befroy D, Frattini J, Shatzkes N, Neschen S, White MF, Bilz S, Sono S, Pypaert M, Shulman GI (2005) Reduced mitochondrial density and increased IRS-1 serine phosphorylation in muscle of insulin-resistant offspring of type 2 diabetic parents. J Clin Invest 115:3587-3593. doi: 10.1172/JCI25151
94. Stratford S, Hoehn KL, Liu F, Summers SA (2004) Regulation of insulin action by ceramide dual mechanisms linking ceramide accumulation to the inhibition of Akt/protein kinase B. J Biol Chem 279:36608-36615. doi:10.1074/jbc.M406499200
95. Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, Defronzo RA, Kirwan JP (2009) Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 58:337-343. doi: 10.2337/db08-1228
96. Coen PM, Dubé JJ, Amati F, Stefanovic-Racic M, Ferrell RE, Toledo FG, Goodpaster BH (2010) Insulin resistance is associated with higher intramyocellular triglycerides in type I but not type II myocytes concomitant with higher ceramide content. Diabetes 59:80-88. doi:10.2337/db09-0988
97. Schnell S, Schaefer M, Schöfl C (2007) Free fatty acids increase cytosolic free calcium and stimulate insulin secretion from bcells through activation of GPR40. Mol Cell Endocrinol 263:173-180. doi:10.1016/j.mice.2006. 09.013
98. Ritz-Laser B, Meda P, Constant I, Klages N, Charollais A, Morales A, Magnan C, Ktorza A, Philippe J (1999) Glucoseinduced preproinsulin gene expression is inhibited by the free fatty acid palmitate. Endocrinology 140:4005-4014. doi: 10.1210/en.140.9.4005
99. Gwiazda KS, Yang TL, Lin Y, Johnson JD (2009) Effects of palmitate on ER and cytosolic Ca2? homeostasis in b-cells. Am J Physiol Endocrinol Metab 296:E690-E701. doi:10.1152/ ajpendo.90525.2008
100. Nakata M, Shintani N, Hashimoto H, Baba A, Yada T (2010) Intra-islet PACAP protects pancreatic beta-cells against glucotoxicity and lipotoxicity. J Mol Neurosci. doi:10.1007/s12031-010-9383-4
101. Branstrom R, Leibiger IB, Leibiger B, Corkey BE, Berggren PO, Larsson O (1998) Long chain coenzyme A esters activate the pore-forming subunit (Kir6.2) of the ATP-regulated potassium channel. J Biol Chem 273:31395-31400. doi:10.1074/ jbc.273.47.31395
102. Liang Y, Buettger C, Berner DK, Matschinsky FM (1997) Chronic effect of fatty acids on insulin release is not through the alteration of glucose metabolism in a pancreatic beta-cell line (beta HC9). Diabetologia 40:1018-1027. doi:10.1007/s0012500 50783
103. Abderrahmani A, Niederhauser G, Favre D, Abdelli S, Ferdaoussi M, Yang JY, Regazzi R, Widmann C, Waeber G (2007) Human high-density lipoprotein particles prevent activation of the JNK pathway induced by human oxidised low-density lipoprotein particles in pancreatic beta cells. Diabetologia 50:1304-1314. doi:10.1007/s00125-007-0642-z
104. Okazaki Y, Eto K, Yamashita T, Okamoto M, Ohsugi M, Noda M, Terauchi Y, Ueki K, Kadowaki T (2010) Decreased insulin secretion and accumulation of triglyceride in beta cells overexpressing a dominant-negative form of AMP-activated protein kinase. Endocr J 57:141-152. doi:10.1507/endocrj.K09E-284
105. Ehses JA, Ellingsgaard H, Boni-Schnetzler M, Donath MY (2009) Pancreatic islet inflammation in type 2 diabetes: from alpha and beta cell compensation to dysfunction. Arch Physiol Biochem 115:240-247. doi:10.1080/13813450903025879
106. Kawamata Y, Imamura T, Babendure JL, Lu JC, Yoshizaki T, Olefsky JM (2007) Tumor necrosis factor receptor-1 can function through a Gaq/11-arrestin-1 signaling complex. J Biol Chem 282:28549-28556. doi:10.1074/jbc.M705869200
107. Jiang B, Yang Y, Jin H, Shang W, Zhou L, Qian L, Chen M (2008) Astragaloside IV attenuates lipolysis and improves insulin resistance induced by TNFa in 3T3-L1 adipocytes. Phytother Res 22:1434-1439. doi:10.1002/ptr.2434
108. Wu JH, Peppel K, Nelson CD, Lin FT, Kohout TA, Miller WE, Exum ST, Freedman NJ (2003) The adaptor protein b-arrestin 2 enhances endocytosis of low density lipoprotein receptor. J Biol Chem 278:44238-44245. doi:10.1074/jbc. M309450200
109. Nelson CD, Perry SJ, Regier DS, Prescott SM, Topham MK, Lefkowitz RJ (2007) Targeting of diacylglycerol degradation to M1 muscarinic receptors by beta-arrestins. Science 315:663-666. doi:10.1126/science.1134562
110. Zhao M, Wimmer A, Trieu K, Discipio RG, Schraufstatter IU (2004) Arrestin regulates MAPK activation and prevents NADPH oxidase-dependent death of cells expressing CXCR2. J Biol Chem 279:49259-49267. doi:10.1074/jbc.M405118200
111. Zhang Z, Hao J, Zhao Z, Ben P, Fang F, Shi L, Gao Y, Liu J, Wen C, Luo L, Yin Z (2009) beta-Arrestins facilitate ubiquitindependent degradation of apoptosis signal-regulating kinase 1 (ASK1) and attenuate H2O2-induced apoptosis. Cell Signal 21:1195-1206. doi:10.1016/j.cellsig.2009.03.010
112. Conner DA, Mathier MA, Mortensen RM, Christe M, Vatner SF, Seidman CE, Seidman JG (1997) beta-Arrestin 1 knockout mice appear normal but demonstrate altered cardiac responses to beta-adrenergic stimulation. Circ Res 81:1021-1026
113. Bohn LM, Lefkowitz RJ, Gainetdinov RR, Peppel K, Caron MG, Lin FT (1999) Enhanced morphine analgesia in mice betaarrestin 2. Science 286:2495-2498. doi:10.1126/science.286. 5449.2495
114. Kohout TA, Lin FS, Perry SJ, Conner DA, Lefkowitz RJ (2001) b-Arrestin 1 and b-arrestin 2 differentially regulate heptahelical receptor signaling and trafficking. Proc Natl Acad Sci USA 98:1601-1606. doi:10.1073/pnas.041608198
115. Sun J, Lin X (2008) beta-Arrestin 2 is required for lysophosphatidic acid-induced NF-jB activation. Proc Natl Acad Sci USA 105:17085-17090. doi:10.1073/pnas.0802701105